Return to NIH Guide Main Index

Since NIDA is one of 27 research institutes and centers comprised of the National Institutes of Health (NIH), NIH manages the grant screening process. We are financing valuable and innovative scientific research on all aspects of drug use and dependence. Information on funding opportunities is available on the NIDA website. All NIH funding opportunities, such as subsidies, contracts, training, SME initiatives, are posted in the NIH Guide. The NIH guide also explains how to apply funds. For answers to more specific questions, please refer to the "Grant and Contract Request Process" page.

NIH is a major gene therapy regulatory body for federal funded research. In order to comply with these regulations, research by private expense is recommended. NIH funds research to develop or enhance genetic engineering technology and evaluates ethics and quality in current research. NIH maintains a mandatory registration of human genetic engineering research agreements, including all federal funded projects. The NIH Advisory Committee published a series of guidelines for genetic manipulation. This guide describes laboratory safety, as well as various types of experiments involving human subjects and genetic changes. There are several sections that specialize in human genetic engineering, including section III-C-1. This section describes the review process and other aspects necessary for seeking approval to start clinical trials, including gene transfer to human patients.

According to the NIH study guide on recombinant or synthetic nucleic acid molecules (NIH guidelines), most clinical trials involving deliberate introduction of transgenic DNA or RNA into humans are consistent with human gene transfer (HGT) requirements I will. HGT research may need to comply with NIH guidelines and may require approval from the IAEA's Biosafety Committee (IBC) based on research products, research locations, and funding sources. IBC's management and administration requires extensive expertise and experience. The WIRB IBC service is a world leader in IBC monitoring of clinical and preclinical research. Since 2000, over 600 research institutes have registered IBC with NIH, over 250 clinical trial protocols have been reviewed and more than 4,000 individual IBC meetings were held. 2850 Fax: (360) 252-2820 E-mail: ibcs@wcgclinical.com